| Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study L Monin, AG Laing, M Muñoz-Ruiz, DR McKenzie, IDM Del Barrio, ... The Lancet Oncology 22 (6), 765-778, 2021 | 589 | 2021 |
| CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment PEM Patten, AGS Buggins, J Richards, A Wotherspoon, J Salisbury, ... Blood, The Journal of the American Society of Hematology 111 (10), 5173-5181, 2008 | 308 | 2008 |
| A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease D Bagnara, MS Kaufman, C Calissano, S Marsilio, PEM Patten, R Simone, ... Blood, The Journal of the American Society of Hematology 117 (20), 5463-5472, 2011 | 298 | 2011 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 297 | 2020 |
| Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ... Nature medicine 28 (2), 325-332, 2022 | 279 | 2022 |
| Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies R Benjamin, C Graham, D Yallop, A Jozwik, OC Mirci-Danicar, G Lucchini, ... The Lancet 396 (10266), 1885-1894, 2020 | 260 | 2020 |
| Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study P Hillmen, AC Rawstron, K Brock, S Muñoz-Vicente, FJ Yates, R Bishop, ... Journal of clinical oncology 37 (30), 2722, 2019 | 250 | 2019 |
| Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience V Shah, TK Ko, M Zuckerman, J Vidler, S Sharif, V Mehra, S Gandhi, ... British Journal of Haematology 190 (5), e279, 2020 | 120 | 2020 |
| Interaction with Vascular Endothelium Enhances Survival in Primary Chronic Lymphocytic Leukemia Cells via NF-κB Activation and De novo Gene Transcription AGS Buggins, C Pepper, PEM Patten, S Hewamana, S Gohil, J Moorhead, ... Cancer research 70 (19), 7523-7533, 2010 | 119 | 2010 |
| Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients S Abdul-Jawad, L Baù, T Alaguthurai, IDM Del Barrio, AG Laing, ... Cancer cell 39 (2), 257-275. e6, 2021 | 109 | 2021 |
| Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP‐9 AGS Buggins, A Levi, S Gohil, K Fishlock, PEM Patten, Y Calle, D Yallop, ... British journal of haematology 154 (2), 216-222, 2011 | 108 | 2011 |
| IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions PEM Patten, CC Chu, E Albesiano, RN Damle, XJ Yan, D Kim, L Zhang, ... Blood, The Journal of the American Society of Hematology 120 (24), 4802-4811, 2012 | 75 | 2012 |
| Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐BCR inhibitor setting: a UK wide analysis TA Eyre, AA Kirkwood, S Gohill, G Follows, R Walewska, H Walter, ... British journal of haematology 185 (4), 656-669, 2019 | 69 | 2019 |
| A national service for delivering CD19 CAR‐T in large B‐cell lymphoma–The UK real‐world experience A Kuhnl, C Roddie, AA Kirkwood, E Tholouli, T Menne, A Patel, C Besley, ... British Journal of Haematology 198 (3), 492-502, 2022 | 68 | 2022 |
| COVID-19 in patients with CLL: improved survival outcomes and update on management strategies LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ... Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021 | 59 | 2021 |
| Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines L Monin-Aldama, AG Laing, M Muñoz-Ruiz, DR McKenzie, ... MedRxiv, 2021.03. 17.21253131, 2021 | 58 | 2021 |
| Risk of COVID-19 death in cancer patients: an analysis from Guy’s Cancer Centre and King’s College Hospital in London B Russell, CL Moss, V Shah, TK Ko, K Palmer, R Sylva, G George, ... British journal of cancer 125 (7), 939-947, 2021 | 52 | 2021 |
| Targeting the tumor microenvironment in chronic lymphocytic leukemia R Svanberg, S Janum, PEM Patten, AG Ramsay, CU Niemann Haematologica 106 (9), 2312, 2021 | 52 | 2021 |
| Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy N Ioannou, PR Hagner, M Stokes, AK Gandhi, B Apollonio, M Fanous, ... Blood, The Journal of the American Society of Hematology 137 (2), 216-231, 2021 | 50 | 2021 |
| Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma A Kuhnl, C Roddie, AA Kirkwood, T Menne, M Cuadrado, MAV Marzolini, ... Blood advances 6 (1), 321, 2022 | 48 | 2022 |
